BiotechTube

Iomab-B + CAR-T cell

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Hodgkin Lymphoma

Conditions

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma

Trial Timeline

Apr 25, 2025 → May 1, 2030

NCT ID
NCT06768905

About Iomab-B + CAR-T cell

Iomab-B + CAR-T cell is a phase 1/2 stage product being developed by Actinium Pharmaceuticals for Non Hodgkin Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06768905. Target conditions include Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma.

What happened to similar drugs?

9 of 20 similar drugs in Non Hodgkin Lymphoma were approved

Approved (9) Terminated (2) Active (9)
✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved
✅rituximab [MabThera/Rituxan]RocheApproved
✅TenofovirGilead SciencesApproved
✅temsirolimus + temsirolimusPfizerApproved
✅Kepivance (Palifermin)Swedish Orphan BiovitrumApproved
✅Entecavir prophylaxis + Therapeutic entecavirBristol Myers SquibbApproved
✅Granulocyte-colony stimulating factor (G-CSF) + Fixed Dose Plerixafor + Weight-Based PlerixaforSanofiApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06768905Phase 1/2Recruiting

Competing Products

20 competing products in Non Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
AFM13AffimedPhase 2
25
VIP152 + BTKiVincerx PharmaPhase 1
11
PLX3397Daiichi SankyoPhase 2
35
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
TirabrutinibOno PharmaceuticalPhase 1
29
ONO-7018Ono PharmaceuticalPhase 1
33
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
32
ONO-7018 + ONO-7018Ono PharmaceuticalPhase 1
33
R-mabHDI and ABVD + ABVDEli LillyPhase 3
36
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
32
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
LY4152199 - IVEli LillyPhase 1
36
R-mabHD + ABVDEli LillyPhase 2
31
enzastaurin + placeboEli LillyPhase 3
40